| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/100-1/200 | Human,Mouse,Rat |
| IHC | 1/50-1/250 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human SV2A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于SV2A抗体的3篇参考文献及其简要摘要：
1. **"Synaptic Vesicle Glycoprotein 2A (SV2A) as a Biomarker of Synaptic Density in Neurodegenerative Diseases"**
- **作者**: Buckley et al.
- **摘要**: 该研究探讨SV2A作为突触密度标志物的潜力，利用SV2A抗体通过免疫组化和PET成像技术，发现其在阿尔茨海默病和帕金森病患者脑组织中表达显著降低，提示其可用于评估突触退行性变。
2. **"Selective Reduction of SV2A Protein in Alzheimer's Disease Animal Models"**
- **作者**: Jing et al.
- **摘要**: 研究使用SV2A抗体检测转基因小鼠模型中的突触小泡蛋白表达，发现SV2A在淀粉样蛋白沉积区域显著减少，表明其与突触功能障碍及认知衰退相关。
3. **"Development and Validation of a High-Affinity SV2A Antibody for Epilepsy Research"**
- **作者**: Lynch et al.
- **摘要**: 报道了一种新型高特异性SV2A抗体的开发，通过Western blot和免疫荧光验证其在啮齿类动物和人类脑组织中的标记效果，证明其适用于癫痫模型中突触可塑性研究。
4. **"Comparative Analysis of SV2A Antibodies in Detecting Synaptic Pathology"**
- **作者**: Smith et al.
- **摘要**: 对比多种市售SV2A抗体的灵敏度和特异性，发现部分抗体在检测啮齿类动物脑切片中的突触损伤时表现更优，为神经科学研究中抗体选择提供了实验依据。
(注：上述文献为示例性内容，实际引用需核对真实出版物信息。)
The synaptic vesicle glycoprotein 2A (SV2A) is an integral membrane protein ubiquitously expressed in synaptic vesicles of neurons, playing a critical role in regulating neurotransmitter release. Discovered in the 1980s, SV2A is part of the SV2 protein family (SV2A, SV2B, SV2C) and is implicated in modulating calcium-triggered exocytosis, though its precise molecular mechanism remains under investigation. Its widespread presence across brain regions and evolutionary conservation highlights its fundamental role in synaptic function.
SV2A gained clinical significance as the binding target of the antiepileptic drug levetiracetam, which modulates synaptic transmission by interacting with SV2A. Antibodies targeting SV2A have emerged as biomarkers in autoimmune encephalitis, particularly in cases overlapping with LGI1 antibody-associated limbic encephalitis. These autoantibodies are detected in cerebrospinal fluid or serum and may contribute to synaptic dysfunction, though their pathogenicity is less defined compared to other neural antibodies.
Research using SV2A-specific antibodies has advanced neuroimaging techniques, enabling PET tracers (e.g., UCB-J) to quantify synaptic density in neurodegenerative diseases like Alzheimer's. Additionally, SV2A knockout models exhibit severe seizures, reinforcing its importance in maintaining neuronal excitability. Ongoing studies explore SV2A's role in synaptic plasticity and its potential as a therapeutic target beyond epilepsy.
×
